Pilarify (piflufolastat f-18) injection x 13
Ended Awarded
- Contract number
- HT941023F0069
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $46,913
Award facts
- Contract value 100% obligated
- $46,913.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
About this award
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The award, valued at $46,913.36, was issued by the Defense Health Agency (DHA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. Progenics is a pharmaceutical company that specializes in innovative diagnostic imaging agents and targeted therapies for oncology.
The contract is a Blanket Purchase Agreement (BPA) call, with a firm fixed price pricing type. It does not have a set-aside designation. Progenics Pharmaceuticals holds several significant federal contract Indefinite Delivery Vehicles (IDVs), including the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, which allows various government healthcare providers to efficiently issue task orders for PYLARIFY and related products. The company's federal contract awards typically involve the supply of radiopharmaceuticals and other products to support medical imaging programs at military treatment facilities, Veterans Affairs medical centers, and other federal healthcare providers.
Quick answers
Who was awarded contract HT941023F0069?
HT941023F0069 was awarded to Progenics Pharmaceuticals Inc. by Defense Health Agency (Department of Defense) on April 10, 2023.
How much is contract HT941023F0069 worth?
The government has obligated $46,913 on HT941023F0069.
Is contract HT941023F0069 an order under another contract?
Yes. HT941023F0069 is a BPA call under HT941023A0002, a blanket purchase agreement.
Was contract HT941023F0069 competed?
The extent of competition for HT941023F0069 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award